The Evolving Role of BTK Inhibitors in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Medical experts detail the current and evolving roles of BTK inhibitors in treatment of patients with relapsed/refractory mantle cell lymphoma.

EP. 1: Defining Oncologic Traits Unique To Mantle Cell Lymphoma

June 21st 2022

Dr Haumschild, PharmD, MS, MBA leads a panel of experts identifying characteristics unique to MCL and addressing initial treatment strategies.

EP. 2: Exploring The Changing Landscape in MCL Treatment

June 21st 2022

Drs Preetesh Jain and Michael Wang exchange insights regarding the current and prospective treatment options for patients with Mantle Cell Lymphoma.

EP. 3: Addressing Unmet Needs in The Relapse/Refractory Setting

June 28th 2022

Preetesh Jain, MBBS, MD, DM, PhD, offers perspective on unmet needs in treatment of patients with relapsed/refractory mantle cell lymphoma.

EP. 4: Key Comorbidity Considerations for Patients With MCL

June 28th 2022

Ryan Haumschild, PharmD, MS, MBA, leads a discussion regarding the treatment of relapsed/refractory mantle cell lymphoma in the presence of comorbidities.